Synthesis and Modification of Targeted Drug Delivery Aptamers

• Anti-Annexin A2 Aptamer Synthesis and Modification Service
• Anti-EpCAM Aptamer Synthesis and Modification Service
• Anti-Epidermal Growth Factor Receptor (EGFR) Aptamer Synthesis and Modification Service
• Anti-Protein Tyrosine Kinase 7 (PTK7) Aptamer Synthesis and Modification Service
• Anti-MUC1 Aptamer Synthesis and Modification Service
• Anti-Transferrin Receptor (TFR) Aptamer Synthesis and Modification Service
• Anti-Nucleolin Aptamer Synthesis and Modification Service
• Anti-GP120 Aptamer Synthesis and Modification Service
• Production-Specific Membrane Antigen (PSMA) Aptamer Synthesis and Modification Service
• Anti-Tenascin-C (TN-C) Aptamer Synthesis and Modification Service

Aptamer has been developed for the treatment of various diseases because of its good binding affinity and specificity. It can be used not only as a therapeutic agent alone, but also as a carrier for covalent or non-covalent binding to drugs for targeted drug delivery.

CD Bioparticles provides synthesis and modification services for targeted drug delivery aptamers, enhancing the binding affinity of aptamers to targets, improving stability and avoiding nuclease degradation in vivo. We have extensive experience in aptamer synthesis and modification, and can provide aptamer synthesis and modification based on your different experimental needs.

Synthesis and Modification of Aptamers Service Background

Rapid advances in aptamer development and nanotechnology have made aptamers an attractive tool for biomedical applications. They can be easily chemically modified and several modifications can be easily achieved without compromising aptamer-target interactions.

Aptamer modifications can enhance binding affinity to the target, improve stability, avoid in vivo nuclease degradation, and enhance their in vivo stability and pharmacokinetics in the biological environment. Many new polymerases can be used to generate a more stable aptamer library that prevents nuclease hydrolysis. In addition, stability can be enhanced by introducing non-natural nucleotides into the library, a process that can be achieved by altering the sugar loop, including 2′-fluoro-ribose, 2′-amino-ribose, 2′-O-methyl-ribose and LNA (covalently linked 2′- and 4′-ribose positions).

Fig.1 SELEX with modified nucleotide bases, sugar rings, or phosphates. (a) Modifications (R) are employed for the selection of SOMAmers including benzyl, naphthyl, and indole (right). (b) Modifications (including F, NH2, OMe, LNA) on sugar rings can be incorporated into aptamers during selection. (c) Increased stability can also be garnered through phosphorothioate (PS) and phosphorodiothioate (PS2) linkages. (Ni S, et al., 2021)

Our Synthesis and Modification of Aptamers Services

CD Bioparticles provides synthesis and modification services for different types of aptamers, enhancing the stability, structural diversity and powerful target binding ability of aptamers in biofluids. We currently offer synthesis and modification services for the following aptamers, but our services are not limited to these:

• Anti-Tenascin-C (TN-C) Aptamer Synthesis and Modification Service
• Production-specific Membrane Antigen (PSMA) Aptamer Synthesis and Modification Service
• Anti-gp120 Aptamer Synthesis and Modification Service
• Anti-Nucleolin Aptamer Synthesis and Modification Service
• Anti-Transferrin Receptor (TFR) Aptamer Synthesis and Modification Service
• Anti-MUC1 Aptamer Synthesis and Modification Service
• Anti-Protein Tyrosine Kinase 7 (PTK7) Aptamer Synthesis and Modification Service
• Anti-Epidermal Growth Factor Receptor (EGFR) Aptamer Synthesis and Modification Service
• Anti-EpCAM Aptamer Synthesis and Modification Service
• Anti-Annexin A2 Aptamer Synthesis and Modification Service

Synthesis and Modification of Aptamers Service Features

• Simple in vitro screening and production process
• Easy modification and coupling of the synthesized aptamers
• High stability and low immunogenicity
• Half-life of modified aptamers can be extended several times compared to unmodified aptamers

Our Synthesis and Modification of Aptamers Services Strengths

• Highly Targeted:

  The service enables the synthesis and modification of oligonucleotide molecules with high affinity and specificity, also known as aptamers, in order to deliver drugs precisely to diseased tissues or cells, thereby improving therapeutic efficacy and reducing unwanted side effects.

• Personalized Therapeutic Research:

  By customizing the structure and sequence of aptamers, it is possible to personalize treatment for different patients or different lesions, thereby improving therapeutic efficacy.

• Efficient:

  Compared to conventional drug delivery systems, aptamer drug delivery offers higher targeting and better biocompatibility, allowing for better therapeutic results at lower drug dosages.

• Highly Controlled:

  By changing the structure and modification of the aptamer, controlled drug release can be achieved, resulting in improved therapeutic efficacy and safety.

• Scaleability:

  Aptamers are not only suitable for the delivery of small molecule drugs but also for the delivery of drugs such as proteins, nucleic acids, and nanoparticles, offering excellent scalability and applicability.

CD Bioparticles provides synthesis and modification services of targeted drug delivery aptamers, enhancing the binding affinity of aptamers to targets, and can provide aptamer synthesis and modification based on your different experimental needs. If you are interested in our services, please do not hesitate to contact us for more detailed information.

Quotations and Ordering

Reference

1. Ni S, Zhuo Z, Pan Y, et al. Recent Progress in Aptamer Discoveries and Modifications for Therapeutic Applications. ACS Appl Mater Interfaces. 2021; 13 (8): 9500-9519.